{
    "nct_id": "NCT03573323",
    "official_title": "A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis",
    "inclusion_criteria": "* Have chronic plaque psoriasis based on a diagnosis for at least 6 months before baseline as determined by the investigator.\n* Are a candidate for phototherapy and/or systemic therapy.\n* Have both an Static Physician Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) score ≥12 at screening and at baseline.\n* Have ≥10% body surface area (BSA) involvement at screening and baseline.\n* If a male, agree to use a reliable method of birth control during the study.\n* If female, agree to use highly effective method of contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.\n* Have a history of drug-induced psoriasis.\n* Had a clinically significant flare of psoriasis during the 12 weeks before baseline.\n* Use of tanning booths for at least 4 weeks before baseline.\n* Concurrent or recent use of any biologic agent within the following periods prior to baseline: etanercept <28 days; infliximab, adalimumab, certolizumab pegol, or alefacept <60 days; golimumab <90 days; rituximab <12 months; secukinumab <5 months; or any other biologic agent (e.g., ustekinumab) <5 half lives.\n* Have prior use of IL-23p19 antagonists (e.g., guselkumab, tildrakizumab, risankizumab), or have any condition or contraindication as addressed in the local labeling for guselkumab that would preclude the participant from participating in this protocol.\n* Have previously completed or withdrawn from this study, participated in any other study with ixekizumab or guselkumab, have participated in any study investigating IL-23p19 antagonists, or have received treatment with ixekizumab.\n* Have previously failed to respond to an IL-17 antagonist, per investigator assessment.\n* Have had a live vaccination within 12 weeks of baseline.\n* Have a known allergy or hypersensitivity to any biologic therapy.\n* Have had any major surgery within 8 weeks of baseline.\n* Have had a serious infection, have been hospitalized, or have received intravenous antibiotics for an infection within 12 weeks of baseline.\n* Are women who are pregnant, or who are lactating (breast-feeding).",
    "miscellaneous_criteria": ""
}